OncLive TV

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, discusses federal funding for research and the importance of gaining funds though private philanthropy to support clinical researchers.

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial that looked at overcoming mTOR resistance with an HDAC inhibitor in renal cell carcinoma (RCC).

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the future of the treatment of colorectal cancer.

Robert Figlin, MD, FACP, discusses an analysis of the heterogeneity of intermediate prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

Robert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses a phase II study that evaluated the efficacy of neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) in patients with inoperable pancreatic adenocarcinoma

Matthew D. Galsky, MD, associate professor, medicine, hematology and medical oncology, assistant professor, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with mCRPC.

Farhad Ravandi, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance in adults with acute myeloid leukemia.

Ari Melnick, MD, professor of medicine, Weill Cornell Medical College, discusses the association between epigenetic diversity and clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL).

Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the challenges of treating patients with Hodgkin's lymphoma.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses markers of resistance in patients with HER2+ breast cancer.

Harry Erba, MD, PhD, discusses the frequency in which patients with chronic-phase chronic myeloid leukemia (CML) fail to achieve a BCR-ABL transcript level below 10% after 3 months of treatment with imatinib.

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in mCRPC.

Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the anti-cancer stem cell antibody OMP-59R5 as a treatment option for patients with metastatic pancreatic cancer.

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting angiogenesis in the treatment of gastric cancer.

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, explains the mechanism of action of dutasteride and its role in a phase II trial in which abiraterone acetate was combined with dutasteride in men with metastatic castration-resistant prostate cancer

Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, describes research involving the ESR1 gene mutation in breast cancer.

Mark R. Litzow. MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses ways of conducting minimal residual disease (MRD) assessments in patients with acute lymphoblastic leukemia

Vincent Miller, MD, Chief Medical Officer, Foundation Medicine, describes FoundationOne, a fully informative genomic profile that launched in 2012.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective study to determine the prognostic value of C-reactive protein (CRP) levels in patients with hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, on clinical trial endpoints and the approval of agents for ovarian cancer.

Alessandra Ferrajoli, MD, discusses the recent approval of ibrutinib for patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy.

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC).

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the potential of CDK inhibition in breast cancer and other malignancies.

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the using immunotherapy agents to treat patients with lung cancer.

Nizar M. Tannir, MD, FACP, from The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses chemotherapy choices for patients with adjuvant breast cancer.